Substance / Medication

Levetiracetam

Overview

Active Ingredient
levetiracetam
RxNorm CUI
114477
Labeler: REMEDYREPACK INC.Updated: 2026-02-12T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

5.4 [see Warnings and Precautions ()] Levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

91 trials linked to this intervention

91
Total Trials
16
Recruiting
33
With Results

Research Evidence

Published studies and systematic reviews

Sort:
How is Levetiracetam Monotherapy Currently Monitored in Pregnancy? A Systematic Review.
Rademaker Tessa, Goo Yeonkyung, Soh May Ching et al. · Clin Pharmacokinet · 2026
PMID: 41120802Meta-AnalysisFull text (PMC)
Levetiracetam for myoclonic seizures in idiopathic generalized epilepsy: A systematic review and meta-analysis.
Pereira Alisson Rafael de Oliveira, Leão Igor Andrade, Dias Lucas Abreu et al. · Epilepsy Behav · 2025
PMID: 40450767Meta-Analysis
Effect of valproic acid and levetiracetam administration on the survival of glioma patients: a meta-analysis study.
Shirani Arya, Obeidinia Mobin, Ziafati Makan et al. · Anticancer Drugs · 2025
PMID: 40699178Meta-Analysis
Efficacy and safety of levetiracetam for pediatric convulsive status epilepticus in emergency settings: a systematic review and meta-analysis.
Alsabri Mohammed, Elsayed Sarah Makram, Rath Shree et al. · BMC Neurol · 2025
PMID: 40739189Meta-AnalysisFull text (PMC)
Efficacy and safety of levetiracetam versus phenobarbitone for neonatal seizures: A systemic review and meta-analysis.
Salim Najwa, Qadri Syeda Iqra, Chughtai Muhammad Aswab Iqbal et al. · Clin Neurol Neurosurg · 2025
PMID: 40975024Meta-Analysis
Levetiracetam versus Phenobarbitone for Management of Neonatal Seizures: A Systematic Review and Meta-analysis.
Kumar Jogender, Yadav Bharti, Meena Jitendra et al. · Indian J Pediatr · 2025
PMID: 37938514Meta-Analysis
Impact of levetiracetam use in glioblastoma: an individual patient-level meta-analysis assessing overall survival.
Vychopen Martin, Güresir Agi, Basaran Alim Emre et al. · Neurosurg Rev · 2024
PMID: 39653818Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Levetiracetam (substance)
SNOMED CT
387000003
UMLS CUI
C0377265
RxNorm CUI
114477
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

4
Conditions
1
Biomarkers
0
Specialists
0
Symptoms
91
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.